Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Philip Keiser, Naiel Nassar, Clinton White, Glenda Koen & Sylvia Moreno. (2002) Comparison of Nevirapine- and Efavirenz-Containing Antiretroviral Regimens in Antiretroviral-Naïve Patients: A Cohort Study. HIV Clinical Trials 3:4, pages 296-303.
Read now
Keiser Philip, Nassar Naiel, White Clinton, Koen Glenda & Moreno Sylvia. (2002) Comparison of Nevirapine- and Efavirenz-Containing Antiretroviral Regimens in Antiretroviral-Naïve Patients: A Cohort Study. HIV Clinical Trials 3:4, pages 296-303.
Read now

Articles from other publishers (11)

Charles F. Haines, John A. Fleishman, Baligh R. Yehia, Bryan Lau, Stephen A. Berry, Allison L. Agwu, Richard D. Moore & Kelly A. Gebo. (2016) Closing the Gap in Antiretroviral Initiation and Viral Suppression: Time Trends and Racial Disparities. JAIDS Journal of Acquired Immune Deficiency Syndromes 73:3, pages 340-347.
Crossref
Khashayar Hesamizadeh, Heidar Sharafi, Mohammad Saeid Rezaee-Zavareh, Bita Behnava & Seyed Moayed Alavian. (2016) Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepatitis Monthly 16:4.
Crossref
Todd M. Ruppar, Fabienne Dobbels, Pawel Lewek, Michal Matyjaszczyk, Kaat Siebens & Sabina M. De Geest. (2015) Systematic Review of Clinical Practice Guidelines for the Improvement of Medication Adherence. International Journal of Behavioral Medicine 22:6, pages 699-708.
Crossref
A.M. PassamG. SourvinosE. KrambovitisS. MiyakisN. StavrianeasI. ZagoreosD.A. Spandidos. (2007) Polymorphisms of Cx 3 CR1 and CXCR6 Receptors in Relation to HAART Therapy of HIV Type 1 Patients . AIDS Research and Human Retroviruses 23:8, pages 1026-1032.
Crossref
Philip Chukwuka Onyebujoh, Isabela Ribeiro & Christopher Curtis Whalen. (2007) Treatment Options for HIV‐Associated Tuberculosis. The Journal of Infectious Diseases 196:s1, pages S35-S45.
Crossref
David R Bangsberg, Edwin D Charlebois, Robert M Grant, Mark Holodniy, Steven G Deeks, Sharon Perry, Kathleen Nugent Conroy, Richard Clark, David Guzman, Andrew Zolopa & Andrew Moss. (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17:13, pages 1925-1932.
Crossref
Carlo Torti, Salvatore Casari, Loredana Palvarini, Eugenia Quiros-Roldan, Francesca Moretti, Luigi Leone, Andrea Patroni, Francesco Castelli, Diego Ripamonti, Andrea Tramarin & Giampiero Carosi. (2003) Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy 65:3, pages 261-267.
Crossref
V. Giner Galvañ, J. Redón i Mas & M.J. Galindo Puertoa. (2003) Hipertensión arterial en pacientes infectados por el virus de la inmunodeficiencia humana. Hipertensión y Riesgo Vascular 20:2, pages 63-73.
Crossref
Connie Yin, Craig R Rayner, Tim Read & Christopher K Fairley. (2002) Association between Self‐Reported Adherence to HIV Therapy and Disease Markers. Journal of Pharmacy Practice and Research 32:4, pages 315-319.
Crossref
Joep Lange. (2000) A Rational Approach to the Selection and Sequencing of Nucleoside/Nucleotide Analogues: A New Paradigm. Antiviral Therapy 6:3_suppl, pages 45-54.
Crossref
Kathleen E Squires. (2000) An Introduction to Nucleoside and Nucleotide Analogues. Antiviral Therapy 6:3_suppl, pages 1-14.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.